As Omicron rages across India, causing a spike in COVID-19 cases, Pune's Gennova Biopharmaceuticals is developing an Omicron-specific vaccine.

The company, according to a spokesperson, has already filed its phase 2 data with Central Drugs Standard Control Organisation (CDSCO). "Gennova Biopharmaceuticals had filed its phase 2 data with CDSCO on Friday. The Omicron specific variant of vaccine is under development and will be ready for human clinical trials, subject to regulatory…

India's Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters.

The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine.

A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that does business in…

India’s Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters.

The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine.

A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that does business in…

The testing of Gennova Biopharmaceutical's mRNA vaccine for the Omicron variant of COVID-19 is subject to regulatory approvals, the company's official spokesperson informed on Monday.

The company spokesperson said, "Omicron specific variant of vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals."Meanwhile, the Pune-based Gennova Biopharmaceuticals has submitted phase 2 data of mRNA vaccine and has also completed the recruitment of…

Pune-based pharmaceutical manufacturer Gennova Biopharmaceuticals Ltd has almost completed the phase 3 trials of its Covid-19 messenger or mRNA vaccine even as the company has started developing an Omicron-specific vaccine using the same technology. Gennova has developed an mRNA vaccine for the Omicron variant, which will be tested for safety and efficacy for use in humans, a Times of India report said.

Messenger RNA or mRNA technology involves the injection of a small part of the…

Gennova Biopharmaceuticals, a Pune-based company which is making India's first mRNA vaccine, has submitted phase-2 trial data of its mRNA Covid-19 vaccine. The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) will review the data soon.

Sources said the company has also developed an Omicron-specific vaccine, which will be tested on humans for efficacy & immunogenicity soon.

During his speech at the 76th United Nations General Assembly (UNGA), Prime…

Pune's Gennova Biopharmaceuticals is developing an Omicron-specific COVID-19 vaccine, a company spokesperson said on Monday. The pharmaceutical manufacturer has already filed its phase 2 data with Central Drugs Standard Control Organisation (CDSCO) on Friday, the spokesperson added.

"Gennova Biopharmaceuticals had filed its phase 2 data with Central Drugs Standard Control Organisation (CDSCO) on Friday. The Omicron specific variant of vaccine is under development & will be ready…

By Shalini Bhardwaj The testing of Gennova Biopharmaceutical's mRNA vaccine for the Omicron variant of COVID-19 is subject to regulatory approvals, the company's official spokesperson informed on Monday.

The company spokesperson said, "Omicron specific variant of vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals." Meanwhile, the Pune-based Gennova Biopharmaceuticals has submitted phase 2 data of mRNA vaccine and has also…

India's Gennova Biopharmaceuticals is working on an Omicron-specific mRNA COVID-19 vaccine candidate, it told Reuters on Monday, after a person with direct knowledge of the matter said the product could be ready in a month or two.

"The Omicron-specific variant of the vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals," a company spokesperson said in a text message. "We will keep you posted."

The source, who did not want to…

Pune-based Gennova Biopharmaceuticals which has been developing India's first mRNA COVID-19 vaccine has submitted phase 2 data of its candidate HGCO19 and has also completed the recruitment of phase 3 data.

Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) is expected to review the data soon.

Gennova Biopharmaceuticals has also developed the mRNA vaccine for the Omicron variant that will be tested on humans for efficacy and immunogenicity starting in…

Pune-based Gennova Biopharmaceuticals which has been developing India's first mRNA COVID-19 vaccine has submitted phase 2 data of its candidate HGCO19 and has also completed the recruitment of phase 3 data.

Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) is expected to review the data soon.

Gennova Biopharmaceuticals has also developed the mRNA vaccine for the Omicron variant that will be tested on humans for efficacy and immunogenicity starting in…

Gennova Biopharmaceuticals, a Pune-based pharmaceutical company, has submitted phase 2 trial data of its mRNA COVID-19 vaccine for approval. The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) is expected to review the data soon.

Gennova Biopharmaceuticals has also completed the recruitment of phase 3 clinical trial data. The pharma company has also developed the mRNA vaccine for the Omicron variant of COVID-19 that will be tested on humans for efficacy &…

Pune-based Gennova Biopharmaceuticals is developing India’s first homegrown mRNA vaccine that will start trials on humans in February.

Gennova submitted the phase 2 trial data to the Drugs Controller General of India (DCGI), and its Subject Expert Committee (SEC) is expected to review the data this week, official sources told news agency ANI.

According to news agency Reuters, the vaccine was found to be “safe, tolerable, and immunogenic” in the participants of an initial…